Table 2.
Mean (SD) Pharmacokinetic Parameters of Ubrogepant Following Single‐Dose Oral Administration of Ubrogepant Alone or in Combination With Sumatriptan in Healthy Adult Participants
| PK Parameter, Mean (SD) | Ubrogepant 100 mg (N = 30) | Ubrogepant 100 mg + Sumatriptan 100 mg (n = 29) |
|---|---|---|
| C max, ng/mL | 400.31 (149.63) | 299.71 (88.77) |
| AUC0‐ t, ng•h/mL | 1566.36 (478.03) | 1606.94 (545.96) |
| AUC0‐∞, ng•h/mL | 1590.47 (480.60) | 1628.20 (550.27) |
| t max, hours† | 1.50 (1.00‐4.00) | 3.00 (1.00‐5.00) |
| t ½, hours‡ | 4.79 (1.48) | 3.87 (0.90) |
| Vz/F, L | 478.73 (227.35) | 394.81 (210.88) |
| CL/F, L/h | 69.06 (23.57) | 69.62 (26.99) |
AUC0‐∞ = area under the plasma drug concentration vs time curve from time 0 to infinity; AUC0‐ t = area under the plasma drug concentration vs time curve from time 0 to time t; CL/F = apparent total clearance of the drug from plasma after oral administration; Cmax = maximum plasma drug concentration; t ½ = mean apparent terminal elimination half‐life; t max = time to maximum plasma drug concentration; Vz/F = apparent volume of distribution during terminal phase after non‐intravenous administration.
†
Median (range).
‡
Mean apparent terminal elimination half‐life.